menu
    • menu

    Find Pevifoscorvir Sodium manufacturers, exporters & distributors on PharmaCompass

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    0

    API Suppliers

    0

    USDMF

    0

    CEP/COS

    0

    JDMF

    0

    EU WC

    0

    KDMF

    0

    NDC API

    0

    VMF

    0

    Listed Suppliers

    0INTERMEDIATES

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    FINISHED DOSAGE FORMULATIONS

    0

    FDF Dossiers

    0

    FDA Orange Book

    0

    Europe

    0

    Canada

    0

    Australia

    0

    South Africa

    0

    Listed Dossiers

    0PROSPECTOR

    3DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    0RELATED EXCIPIENT COMPANIES

    0EXCIPIENTS BY APPLICATIONS

    PATENTS & EXCLUSIVITIES

    0

    US Patents

    0

    US Exclusivities

    0

    Health Canada Patents

    GLOBAL SALES INFORMATION

    US Medicaid

    NA

    Annual Reports

    NA

    Regulatory FDF Prices

    NA

    MARKET PLACE

    0

    API

    0

    FDF

    DIGITAL CONTENT

    0

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    1

    News #PharmaBuzz

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 2495324-72-4, Orb2945464, Quf596z92t, Schembl29453418, Pevifoscorvir sodium [usan], Alg000184
    Molecular Formula
    C23H20FN4Na2O8P
    Molecular Weight
    576.4  g/mol
    InChI Key
    AZODBEIBQSHYDI-UHFFFAOYSA-L
    FDA UNII
    QUF596Z92T
    Pevifoscorvir Sodium
    1 2D Structure

    Pevifoscorvir Sodium

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    disodium;[[2-[5-[(3-cyano-4-fluorophenyl)carbamoyl]-1,2,4-trimethylpyrrol-3-yl]-2-oxoacetyl]-(3-ethynyloxetan-3-yl)amino]methyl phosphate
    2.1.2 InChI
    InChI=1S/C23H22FN4O8P.2Na/c1-5-23(10-35-11-23)28(12-36-37(32,33)34)22(31)20(29)18-13(2)19(27(4)14(18)3)21(30)26-16-6-7-17(24)15(8-16)9-25;;/h1,6-8H,10-12H2,2-4H3,(H,26,30)(H2,32,33,34);;/q;2*+1/p-2
    2.1.3 InChI Key
    AZODBEIBQSHYDI-UHFFFAOYSA-L
    2.2 Other Identifiers
    2.2.1 UNII
    QUF596Z92T
    2.3 Synonyms
    2.3.1 Depositor-Supplied Synonyms

    1. 2495324-72-4

    2. Orb2945464

    3. Quf596z92t

    4. Schembl29453418

    5. Pevifoscorvir Sodium [usan]

    6. Alg000184

    7. T204624

    8. 1h-pyrrole-3-acetamide, 5-[[(3-cyano-4-fluorophenyl)amino]carbonyl]-n-(3-ethynyl-3-oxetanyl)-1,2,4-trimethyl-alpha-oxo-n-[(phosphonooxy)methyl]-, Sodium Salt (1:2)

    9. Disodium [[2-[5-[(3-cyano-4-fluorophenyl)carbamoyl]-1,2,4-trimethylpyrrol-3-yl]-2-oxoacetyl]-(3-ethynyloxetan-3-yl)amino]methyl Phosphate

    10. Disodium;[[2-[5-[(3-cyano-4-fluorophenyl)carbamoyl]-1,2,4-trimethylpyrrol-3-yl]-2-oxoacetyl]-(3-ethynyloxetan-3-yl)amino]methyl Phosphate

    2.4 Create Date
    2021-02-21
    3 Chemical and Physical Properties
    Molecular Weight 576.4 g/mol
    Molecular Formula C23H20FN4Na2O8P
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count10
    Rotatable Bond Count8
    Exact Mass Da
    Monoisotopic Mass Da
    Topological Polar Surface Area177
    Heavy Atom Count39
    Formal Charge0
    Complexity1060
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count3

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Aligos Therapeutics Licenses Pevifoscorvir Sodium to Xiamen Amoytop for Chronic Hepatitis B in China

    Details:

    Through the licensing deal for Pevifoscorvir Sodium, targeting HBV capsid, the agreement aims to advance treatment for Chronic Hepatitis B Infection.


    Lead Product(s): Pevifoscorvir Sodium,Inapplicable

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Miscellaneous

    Sponsor: Xiamen Amoytop Biotech Co., Ltd

    Deal Size: $445.0 million Upfront Cash: $25.0 million

    Deal Type: Licensing Agreement April 16, 2026

    blank

    01

    Aligos Therapeutics

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed

    Aligos Therapeutics

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pevifoscorvir Sodium,Inapplicable

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Xiamen Amoytop Biotech Co., Ltd

    Deal Size : $445.0 million

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Aligos Therapeutics Licenses Pevifoscorvir Sodium to Xiamen Amoytop for Chronic Hepatitis B in Chi...

    Details : Through the licensing deal for Pevifoscorvir Sodium, targeting HBV capsid, the agreement aims to advance treatment for Chronic Hepatitis B Infection.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : $25.0 million

    April 16, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impa...

    Details:

    ALG-000184 (Pevifoscorvir Sodium) is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of hepatitis b.


    Lead Product(s): Pevifoscorvir Sodium,Inapplicable

    Therapeutic Area: Infections and Infectious Diseases Brand Name: ALG-000184

    Study Phase: Phase IProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable January 15, 2026

    blank

    02

    Aligos Therapeutics

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed

    Aligos Therapeutics

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pevifoscorvir Sodium,Inapplicable

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodi...

    Details : ALG-000184 (Pevifoscorvir Sodium) is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of hepatitis b.

    Product Name : ALG-000184

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    January 15, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment a...

    Details:

    ALG-000184 (Pevifoscorvir Sodium) is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of hepatitis b.


    Lead Product(s): Pevifoscorvir Sodium,Inapplicable

    Therapeutic Area: Infections and Infectious Diseases Brand Name: ALG-000184

    Study Phase: Phase IProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable January 15, 2026

    blank

    03

    Aligos Therapeutics

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed

    Aligos Therapeutics

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pevifoscorvir Sodium,Inapplicable

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodiu...

    Details : ALG-000184 (Pevifoscorvir Sodium) is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of hepatitis b.

    Product Name : ALG-000184

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    January 15, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search